Drugs Home > Ibritumomab Dosage

Before prescribing a specific ibritumomab dosage, your healthcare provider will take into consideration your weight and platelet count. This medication comes as an injection that is given intravenously by your healthcare provider. You only need one dose of this medicine, which is given within four hours after a second dose of another medicine known as rituximab.

An Introduction to Your Dosage of Ibritumomab

The dose of ibritumomab (Zevalin®) your healthcare provider recommends will vary, depending on your platelet count and your weight. As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.

Ibritumomab Dosing Guidelines

Ibritumomab is used as part of a treatment regimen that includes rituximab (Rituxan®). On the first day of treatment, you will receive rituximab via an intravenous (IV) infusion (a slow drip into a vein). The dose of rituximab you receive will depend on your body surface area, which is calculated using your height and weight.
Six to eight days later (days seven, eight, or nine of the treatment regimen), you will receive your second dose of rituximab. Ibritumomab will be given within four hours of this second rituximab dose.
The ibritumomab dosage is expressed in units of radioactivity, known as the Becquerel (Bq). The usual dose in people with a normal platelet count is 14.8 megabecquerel per kilogram body weight (MBq per kg), or about 6.7 MBq per pound. The dose should not exceed 1184 MBq, regardless of body weight.
The usual recommended dosage in people with a low platelet count is 11.1 MBq per kg (about 5 MBq per pound). People with an extremely low platelet count (less than 100,000 platelets per mm3) should not receive ibritumomab.
You will be given other medications before receiving your dose of rituximab. This is known as "premedication." Premedication normally includes acetaminophen (Tylenol®) 650 mg and diphenhydramine (Benadryl® and others) 50 mg, taken by mouth. These medications are used to help limit the chance and severity of an infusion reaction, a potentially dangerous reaction that can occur from your dose.
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation

Topics & Medications


Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.